Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Omeros Corporation
ClinicalTrials.gov Identifier:
NCT01406561
First received: July 28, 2011
Last updated: January 3, 2013
Last verified: January 2013

July 28, 2011
January 3, 2013
August 2011
November 2012   (final data collection date for primary outcome measure)
  • KOOS Symptoms Subscale [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee symptoms as measured by the KOOS Symptoms subscale through Day 30.
  • Safety [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
    To evaluate the safety of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on safety as measured by adverse events.
  • Knee Symptoms [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee symptoms as measured by the Knee Injury and Osteoarthritis Outcome Score Symptoms subscale through Day 30.
  • Safety [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
    To evaluate the safety of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on safety as measured by adverse events.
Complete list of historical versions of study NCT01406561 on ClinicalTrials.gov Archive Site
  • Knee Function in Sport Active patients [ Time Frame: 30 Days ] [ Designated as safety issue: No ]
    To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee function as measured by the KOOS Sports and Recreation subscale through Day 30 in the subset of subjects who participate in sports.
  • Knee Pain [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee pain as measured by the KOOS Pain subscale through Day 30.
  • Quality of Life [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee quality of life as measured by the KOOS Quality of Life subscale through Day 30.
  • Knee Function [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee function as measured by the KOOS Activites of Daily Living subscale through Day 30.
  • Postoperative Knee Pain [ Time Frame: Day of Surgery (day 1) ] [ Designated as safety issue: No ]
    To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on postoperative knee pain as measured by the Visual Analog Scale during the day of surgery.
  • Passive Flexion [ Time Frame: 7 Days ] [ Designated as safety issue: No ]
    To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on Passive flexion on Day 7.
Same as current
Not Provided
Not Provided
 
Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy
A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy

The purpose of this study is to assess the effect of OMS103HP solution for Injection (OMS103HP-S) and function as measured by the Knee Osteoarthritis Outcome Survey (KOOS) Symptoms subscale through Day 30 compared with vehicle irrigation solution for knee symptoms in subjects undergoing meniscectomy.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Meniscal Tear
  • Drug: OMS103HP-S
    Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
  • Drug: Vehicle
    3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
  • Experimental: OMS103HP-S
    OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
    Intervention: Drug: OMS103HP-S
  • Placebo Comparator: Vehicle Irrigation Solution
    Vehicle Irrigation Solution
    Intervention: Drug: Vehicle
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
344
December 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Voluntarily provide written informed consent in accordance with governing Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements, local regulations, and Health Insurance Portability and Accountability Act (HIPAA) Authorization (or equivalent if locally applicable)
  2. In the opinion of the Investigator are able to comply with study-required visits and procedures
  3. 18 to 75 years of age, inclusive at the time of screening
  4. Have a traumatic or degenerative meniscal cartilage injury (full thickness tear) that occurred at least 14 days prior to the day of arthroscopic surgery that is demonstrated on MRI
  5. Planning to undergo unilateral arthroscopic meniscectomy
  6. If female and of childbearing potential (i.e., not surgically sterilized or post-menopausal for longer than one year), agree to use a medically accepted method of birth control for the duration of her study involvement
  7. At minimal risk from anesthesia and classified according to the American Society of Anesthesiologists Physical Status Classification as either PS-1 (a normal healthy patient) or PS-2 (a patient with mild systemic disease that results in no functional limitation) as determined by the Investigator.

Exclusion Criteria:

  1. Significant arthritis in the surgical knee (Grade 3 or 4 on the Kellgren- Lawrence Grading Scale).
  2. History of reactive synovial disease
  3. History of a complex regional pain syndrome (Type I, i.e., reflex sympathetic dystrophy, or Type II, i.e., causalgia), chronic pain, attendance at a chronic pain clinic, or neurologic disorder associated with sensory deficit of the lower extremities
  4. History of fibromyalgia
  5. Expected to undergo any of the following procedures concurrent with the meniscectomy:

    • Meniscal repair procedure
    • Patellar tendon debridement
    • Patellar realignment
    • Lateral or retinacular release
    • Excision synovectomy (minor synovectomy to improve arthroscopic visualization is allowed)
    • Concurrent ligamentous procedure
    • Abrasion chondroplasty involving bone
    • Microfracture
    • Chondral transplantation
    • Use of more than three portals
  6. Known allergies to any of the individual ingredients in OMS103HP-S, other NSAIDs, aspirin, tricyclic antidepressants, or opioid analgesics
  7. Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
  8. Have a job-related claim(s) under dispute or mediation
  9. History of drug or alcohol abuse
  10. Treatment with an investigational drug or device within 30 days prior to the day of surgery
  11. A clinically significant medical condition that in the opinion of the Investigator would put the subject at increased risk, impair the subject's ability to comply with the requirements of the protocol, or confound the interpretation of the data
  12. Expected to receive a regional block for analgesia for this procedure
  13. Considered by the Investigator for any reason to be an unsuitable candidate for receipt of an investigational drug
  14. The Investigator, employee of the investigative site, and/or part of the Investigator/employee's immediate families (defined as current spouse or partner, parent, natural or legally adopted child, stepchild living in the household, grandparent, or grandchild).
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01406561
OMS103-MEN-002
No
Omeros Corporation
Omeros Corporation
Not Provided
Study Director: Steve Whitaker, MD Omeros Corporation
Omeros Corporation
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP